A couple files a permanent hair loss after Taxotere lawsuit against the makers of the chemotherapy drug, alleging the drug caused permanent hair loss side effects, also known as alopecia.

Plaintiffs Aisha A. and Ali A. file the permanent hair loss after Taxotere lawsuit in Louisiana federal court, joining a growing multidistrict litigation (MDL) against the company.

According to the permanent hair loss after Taxotere lawsuit, the plaintiffs are residents of the state of North Carolina. Aisha, who was prescribed the medication, says that she was taking Taxotere from April 10, 2013, through June 5, 2013.

Aisha’s alleged injuries include permanent hair loss side effects, while Ali files for loss of consortium damages.

The permanent hair loss after Taxotere lawsuit was filed on multiple counts including failure to warn, negligence, negligent misrepresentation, fraudulent misrepresentation, fraudulent concealment, and fraud and deceit.

Permanent Hair Loss After Taxotere

Aisha’s claim is filed as part of a large MDL centered on allegations that Taxotere causes permanent and disfiguring hair loss, a side effect of the chemo drug that the manufacturers allegedly failed to warn about.

The Taxotere lawsuits filed against the drug’s manufacturer, Sanofi Aventis, state that the company knew or should have known about Taxotere permanent hair loss side effects and that the company should have properly warned of this severe risk.

Other allegations accuse the company of selling a defective, unsafe, and inherently dangerous product; of negligently designing and manufacturing Taxotere; of causing patients to suffer permanent hair loss side effects because of their omissions and lack of warnings; and of failing to adequately test the safety of Taxotere.

There are claims that while permanent hair loss side effects of Taxotere were warned about in Europe and Canada, no such warnings were made in the U.S. until 2015; nearly 20 years after the drug was introduced to the market.

Taxotere was initially approved by the U.S. Food and Drug Administration (FDA) in May 2004. Marketing statements made by Sanofi Aventis simply stated that hair loss “generally” grows back.

A permanent hair loss after Taxotere lawsuit, like the one filed by Aisha, can provide compensation of a range of Taxotere-related losses such as:
• Mental anguish
• Emotional distress
• Diminished quality of life
• Permanent disfigurement
• Loss of earnings and lost earning potential

Those eligible to file a permanent hair loss after Taxotere lawsuit include those who took Taxotere as part of a chemotherapy treatment plan, developed permanent hair loss (or permanent alopecia) because of the drug taken as diagnosed by a medical doctor, and can demonstrate loss due to permanent hair loss side effects.

Several studies have been conducted associating Taxotere with permanent hair loss side effects, including one conducted in 2006 by a team of researchers of the Rocky Mountain Cancer Centers in Denver. They found, in the study led by Dr. Scot Sedlacek, that 6.3 percent of patients grew back less than 50 percent of their hair after Taxotere use.

According to the study, “when docetaxel is administered … there is a small but significant possibility of poor hair regrowth lasting up to [seven] years. Such an emotionally devastating long term toxicity from this combination must be taken into account when deciding on adjuvant chemotherapy programs in women who likely will be cured of their breast cancer.”

The Permanent Hair Loss After Taxotere Lawsuit is Case No. 2:18-cv-02461-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana. The Taxotere MDL is in re: Taxotere (Docetaxel) Products Liability Litigation, MDL No. 2740, in the same court.